Cargando…
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis
BACKGROUND: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF‐related splenomega...
Autores principales: | Palandri, Francesca, Bartoletti, Daniela, Iurlo, Alessandra, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Caocci, Giovanni, Elli, Elena M., Auteri, Giuseppe, Tiribelli, Mario, Polverelli, Nicola, Miglino, Maurizio, Heidel, Florian H., Tieghi, Alessia, Benevolo, Giulia, Beggiato, Eloise, Fava, Carmen, Cavazzini, Francesco, Pugliese, Novella, Binotto, Gianni, Bosi, Costanza, Martino, Bruno, Crugnola, Monica, Ottaviani, Emanuela, Micucci, Giorgia, Trawinska, Malgorzata M., Cuneo, Antonio, Bocchia, Monica, Krampera, Mauro, Pane, Fabrizio, Lemoli, Roberto M., Cilloni, Daniela, Vianelli, Nicola, Cavo, Michele, Palumbo, Giuseppe A., Breccia, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325504/ https://www.ncbi.nlm.nih.gov/pubmed/35363892 http://dx.doi.org/10.1002/cncr.34216 |
Ejemplares similares
-
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023) -
P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023) -
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023) -
P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022) -
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)